Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol (2014) 2.15

Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci (2009) 2.04

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood (2012) 2.03

Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood (2006) 1.47

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood (2007) 1.40

EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst (2009) 1.37

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood (2013) 1.09

Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (Landmark Ed) (2013) 1.01

Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev (2008) 1.00

Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev (2011) 1.00

Novel drugs for older patients with acute myeloid leukemia. Leukemia (2014) 0.99

EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res (2010) 0.95

Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood (2011) 0.92

SIGLEC12, a human-specific segregating (pseudo)gene, encodes a signaling molecule expressed in prostate carcinomas. J Biol Chem (2011) 0.91

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). Br J Haematol (2010) 0.89

Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. PLoS One (2011) 0.88

Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel) (2011) 0.87

In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin. Eur J Nucl Med Mol Imaging (2010) 0.87

Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin. Leukemia (2012) 0.87

Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics. Biomol Ther (Seoul) (2015) 0.86

Frozen cord blood hematopoietic stem cells differentiate into higher numbers of functional natural killer cells in vitro than mobilized hematopoietic stem cells or freshly isolated cord blood hematopoietic stem cells. PLoS One (2014) 0.86

CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. Haematologica (2011) 0.86

Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial. Haematologica (2016) 0.78

Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. Haematologica (2013) 0.78

Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. Blood (2008) 0.77

Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody. MAbs (2015) 0.76

Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. Invest New Drugs (2002) 0.76

Antibody Drug Conjugates: Preclinical Considerations. AAPS J (2015) 0.75

Enhanced lentiviral vector production in 293FT cells expressing Siglec-9. Cytotechnology (2014) 0.75

Linkers Having a Crucial Role in Antibody-Drug Conjugates. Int J Mol Sci (2016) 0.75

Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013). Ann Hematol (2015) 0.75

SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells. Oncotarget (2017) 0.75

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer Res (2015) 0.75

Acute myeloid leukemia targets for bispecific antibodies. Blood Cancer J (2017) 0.75

The optimal dosing of gemtuzumab ozagamicin: where to go from here? Haematologica (2016) 0.75

Effect of antigen-dependent clearance on pharmacokinetics of anti-heparin-binding EGF-like growth factor (HB-EGF) monoclonal antibody. MAbs (2014) 0.75

Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy (2016) 0.75

Targeting alternatively spliced sequence features for cancer diagnosis and therapeutics. J Gastroenterol (2005) 0.75

Emerging therapies for acute myeloid leukemia: translating biology into the clinic. JCI Insight (2017) 0.75

High gamma power is phase-locked to theta oscillations in human neocortex. Science (2006) 10.40

Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat Med (2000) 4.55

Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr (1997) 3.80

Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med (2000) 3.70

Diagnosis and management of pituitary abscess: a review of twenty-four cases. J Neurosurg (2001) 3.00

The gene encoding the epsilon subunit of the T3/T-cell receptor complex maps to chromosome 11 in humans and to chromosome 9 in mice. Proc Natl Acad Sci U S A (1987) 2.91

Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res (2001) 2.78

Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg (1998) 2.75

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71

DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ (2006) 2.57

Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. J Cell Sci (2000) 2.57

Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J Immunol (1993) 2.56

Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest (1988) 2.53

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood (2001) 2.53

Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg (2001) 2.39

Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood (1986) 2.27

Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer (1987) 2.27

Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha/beta lineage: T cell receptor delta gene deletion mechanism affects multiple genes. J Exp Med (1993) 2.23

Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom (2004) 2.20

Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res (2001) 2.16

A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11

Cortical localization of temporal lobe language sites in patients with gliomas. Neurosurgery (1994) 2.07

The Notch ligand, Jagged-1, influences the development of primitive hematopoietic precursor cells. Blood (1998) 2.05

Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med (1989) 2.05

Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst (1971) 2.04

E2A and EBF act in synergy with the V(D)J recombinase to generate a diverse immunoglobulin repertoire in nonlymphoid cells. Mol Cell (2000) 1.99

Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood (1999) 1.90

T cell receptor excision circles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for interpretation. J Mol Med (Berl) (2001) 1.86

Epidermoid cysts of the posterior fossa. J Neurosurg (1985) 1.85

Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery (1994) 1.85

Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia (1999) 1.83

p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res (2001) 1.80

A human homologue of the Drosophila developmental gene, Notch, is expressed in CD34+ hematopoietic precursors. Blood (1994) 1.74

Indocyanine green (ICG) staining and demarcation of tumor margins in a rat glioma model. Surg Neurol (1993) 1.72

The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol (1999) 1.71

Patient literacy and the readability of written cancer educational materials. Oncol Nurs Forum (1995) 1.70

Confidentiality and health insurance fraud. Arch Intern Med (1997) 1.68

Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia (1998) 1.68

Flow cytometric analysis of the Vbeta repertoire in healthy controls. Cytometry (2000) 1.66

Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood (1991) 1.64

Distinct molecular forms of human T cell receptor gamma/delta detected on viable T cells by a monoclonal antibody. J Exp Med (1988) 1.62

Suitable DNA isolation method for the detection of minimal residual disease by PCR techniques. Leukemia (1999) 1.61

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia (2012) 1.60

Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res (2001) 1.59

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia (2012) 1.57

Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia (1999) 1.55

Unique selection determinant in polyclonal V delta 2-J delta 1 junctional regions of human peripheral gamma delta T lymphocytes. J Immunol (1994) 1.54

Inhibition of granulocytic differentiation by mNotch1. Proc Natl Acad Sci U S A (1996) 1.54

Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. Blood (2001) 1.52

Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy. Proc Natl Acad Sci U S A (2000) 1.50

[Immunology in medical practice. XXXV. Screening of suspected immunodeficiency: diagnostic protocols for patients with opportunistic or recurrent severe infections, wasting and failure to thrive]. Ned Tijdschr Geneeskd (2000) 1.50

Primary central nervous system tumors: advances in knowledge and treatment. CA Cancer J Clin (1998) 1.49

Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J Natl Cancer Inst (1972) 1.48

Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol (2007) 1.47

Interleukin-3, GM-CSF, and G-CSF receptor expression on cell lines and primary leukemia cells: receptor heterogeneity and relationship to growth factor responsiveness. Blood (1989) 1.47

Human hematopoietic precursors in long-term culture: single CD34+ cells that lack detectable T cell, B cell, and myeloid cell antigens produce multiple colony-forming cells when cultured with marrow stromal cells. J Exp Med (1990) 1.47

Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2. Cancer Res (1995) 1.46

Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Childrens Cancer Group. J Clin Oncol (1994) 1.45

Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res (2001) 1.45

[Widely divergent clinical phenotype of x-linked agammaglobulinemia in two cousins]. Ned Tijdschr Geneeskd (2004) 1.44

Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res (1997) 1.43

Minimal residual disease in leukaemia patients. Lancet Oncol (2001) 1.43

Absorption of antigens from the gastrointestinal tract. Int Arch Allergy Appl Immunol (1968) 1.43

Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res (1996) 1.42

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia (2010) 1.42

All-trans retinoic acid enhances the long-term repopulating activity of cultured hematopoietic stem cells. Blood (2000) 1.39

Invasive Aspergillus infection in chronic granulomatous disease: treatment with itraconazole. J Pediatr (1989) 1.39

Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res (1996) 1.38

Preferential rearrangements of the T cell receptor-delta-deleting elements in human T cells. J Immunol (1997) 1.36

Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin Cancer Res (2001) 1.36

O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res (1999) 1.34

Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol (1985) 1.33

Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia (1997) 1.33

Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med (1987) 1.32

Membrane targeting of cGMP-dependent protein kinase is required for cystic fibrosis transmembrane conductance regulator Cl- channel activation. Proc Natl Acad Sci U S A (1998) 1.31

Functional cortex and subcortical white matter located within gliomas. Neurosurgery (1996) 1.31

Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood (1999) 1.31

Expression of normal myeloid-associated antigens by acute leukemia cells. Blood (1986) 1.30

Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen. Science (1980) 1.30

The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood (1986) 1.29

Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res (1994) 1.29

Specific in vivo localization of monoclonal antibodies directed against the Thy 1.1 antigen. J Immunol (1980) 1.29

Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood (1994) 1.28

Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia (2001) 1.28

Outcome from severe head injury in children and adolescents. J Neurosurg (1985) 1.27

Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res (1996) 1.27

Human immunodeficiency virus infection studied in CD4-expressing human-murine T-cell hybrids. Virology (1989) 1.26

The Notch ligand, Delta-1, inhibits the differentiation of monocytes into macrophages but permits their differentiation into dendritic cells. Blood (2001) 1.26

Notch signalling in hematopoiesis. Semin Cell Dev Biol (2003) 1.26

Monocytes express high amounts of Notch and undergo cytokine specific apoptosis following interaction with the Notch ligand, Delta-1. Blood (2000) 1.26

Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol (1990) 1.26

BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia (2000) 1.24

All-trans retinoic acid delays the differentiation of primitive hematopoietic precursors (lin-c-kit+Sca-1(+)) while enhancing the terminal maturation of committed granulocyte/monocyte progenitors. Blood (1999) 1.24

Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors. Neurosurgery (2000) 1.24

Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood (1983) 1.23

TCR gene rearrangements and expression of the pre-T cell receptor complex during human T-cell differentiation. Blood (1999) 1.22

Sub-centimeter language organization in the human temporal lobe. Brain Lang (2010) 1.22